Correlations between anti-TNF-α agents and increased risks of serious infection (non-gastrointestinal bacterial infection requiring hospitalization) [34], and TB [35,36,37] and hepatitis B [38] reactivation have been reported. The gene discussed is TNF; the disease is tuberculosis.